On June 6, 2025, Ascendiant Capital has reaffirmed its 'Buy' rating for Lucid Diagnostics (LUCD, Financial). The firm, led by analyst Edward Woo, has maintained its positive outlook on the company's stock, providing continued confidence for investors.
Additionally, Ascendiant Capital has raised its price target for Lucid Diagnostics (LUCD, Financial) from $7.50 to $7.75 USD. This adjustment represents a 3.33% increase, reflecting the analyst's optimistic projection on the company's potential growth and performance.
Investors should note that the prior valuation for Lucid Diagnostics (LUCD, Financial) was set at $7.50 USD, underlining the recent upward revision by the analyst in response to the company's market activities and expectations.
Lucid Diagnostics (LUCD, Financial) remains a stock to watch, as the maintained 'Buy' rating and revised price target suggest a favorable position in the current market landscape.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 6 analysts, the average target price for Lucid Diagnostics Inc (LUCD, Financial) is $3.75 with a high estimate of $7.50 and a low estimate of $2.00. The average target implies an upside of 207.38% from the current price of $1.22. More detailed estimate data can be found on the Lucid Diagnostics Inc (LUCD) Forecast page.
Based on the consensus recommendation from 6 brokerage firms, Lucid Diagnostics Inc's (LUCD, Financial) average brokerage recommendation is currently 1.8, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Lucid Diagnostics Inc (LUCD, Financial) in one year is $4.69, suggesting a upside of 284.43% from the current price of $1.22. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Lucid Diagnostics Inc (LUCD) Summary page.
